NAD+ 1000
The coenzyme behind cellular energy and repairCellular energy and repair support, dosed in monthly cycles and scheduled with your consultant alongside baseline diagnostics.
NAD+ levels roughly halve between young adulthood and middle age. Restoring them supports the enzymes behind energy metabolism and DNA repair, the clinical evidence is emerging, and your consultant will be direct about what is and isn’t established. Full reference →
Who this is for
Adults with persistent fatigue, poor recovery, or a longevity focus, where baseline diagnostics support supplementation. Candidacy is decided with your consultant against your history and labs, never by a checkout flow.
How the program works
Your consultant goes through your goals, history, and whether this therapy is appropriate. If it isn't, you'll hear that instead.
An at-home blood draw establishes your baseline. Your pen ships cold-chain once your program is agreed.
Dosing runs in monthly cycles with rest weeks set with your consultant, and messaging in between.
Repeat labs against your baseline. Together you decide: continue, adjust the cycle, or stop with a plan.
Common questions
Some patients report changes in energy and sleep within the first cycle; for others it is gradual. Your consultant reviews your labs and how you feel at week 12 rather than promising a date.
Subcutaneous pens give steadier levels than occasional IV drips and fit daily life. If an IV loading phase makes sense for you, your consultant will say so, but it isn't the default.
Your program is quoted in full after your consultation, before anything is supplied. There is no set program price because there is no off-the-shelf product: dose, cycle length and monitoring differ per patient.
NAD+ stands for nicotinamide adenine dinucleotide, in its oxidised form. The "+" denotes the positively-charged nicotinamide ring nitrogen. NAD+ is a coenzyme present in all eukaryotic cells and functions as the principal electron carrier in cellular bioenergetics. It is technically a coenzyme, not a peptide, but is commonly supplied alongside research peptides in pen format.
No. NAD+ has no FDA approval as a pharmaceutical. It is supplied as a research compound for laboratory use only. NMN and NR (precursors) have been studied in human trials but have not received regulatory approval as therapeutic agents in any jurisdiction.
NAD+ research applications cover cellular bioenergetics, sirtuin pathway pharmacology, age-related metabolic decline, PARP and CD38 substrate research, and the precursor pathway literature (NMN, NR comparisons). The Imai and Guarente 2014 Trends in Cell Biology review and the Mills 2016 Cell Metabolism long-term NMN paper provide widely-cited research entry points.
The cell’s electron carrier
NAD+ functions as the principal electron carrier in cellular bioenergetics, cycling between oxidised (NAD+) and reduced (NADH) forms across the citric acid cycle, glycolysis, beta-oxidation, and the electron transport chain. The redox cycling is the most fundamental role and the one shared with all eukaryotic cells.
Sirtuins (SIRT1-SIRT7) are NAD+-dependent deacetylases that regulate metabolism, DNA damage response, and gene expression. Imai and Guarente (Trends Cell Biol, 2014;24(8):464-471) reviewed how NAD+ availability is rate-limiting for sirtuin activity and how the age-related decline in tissue NAD+ contributes to age-associated metabolic dysfunction.
NAD+ is consumed (not just cycled) by poly-ADP-ribose polymerases (PARPs) during DNA damage repair and by CD38 in inflammatory signalling. The consumption pathways compete with sirtuins for NAD+ pool, providing the mechanistic basis for the "NAD+ depletion" framing common in aging biology research.
NAD+ is regenerated from nicotinamide via the salvage pathway, with nicotinamide phosphoribosyltransferase (NAMPT) as the rate-limiting enzyme. NMN and NR are intermediates that bypass NAMPT and raise tissue NAD+ levels (Mills et al, Cell Metab, 2016;24(6):795-806).
NAD 1000 is also searched as Nicotinamide adenine dinucleotide, NAD.